Chronic wounds represent one of healthcare’s largest and most persistent clinical challenges, affecting more than 8 million people in the US alone and generating tens of billions of dollars in annual treatment costs. The sector spans advanced wound dressings, negative pressure wound therapy, antimicrobial technologies, skin substitutes, and a rapidly expanding regenerative medicine segment.
Demand is being driven by structural healthcare trends, including ageing populations, rising diabetes prevalence, and increasing surgical volumes. Between 19% and 34% of people with diabetes will develop a foot ulcer during their lifetime, contributing to millions of complex wound cases globally each year.
As innovation accelerates, wound care companies are starting to balance two very different markets: high-volume established therapies and sophisticated, innovative technologies. Commercializing a $500 regenerative biologic requires a fundamentally different strategy than a $5 foam dressing. This creates demand for leaders who can adapt to new developments while catering to the needs of high-volume, legacy treatments.